Overview


According to FutureWise analysis, the market for Sprycel is expected to grow with a CAGR of 5.72% over the forecast period 2024-2032, and reach a market value of US$ 6.33 Billion by 2031. 

Sprycel, known by its generic name dasatinib, is a prescribed medication primarily employed in managing chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It falls under tyrosine kinase inhibitors (TKIs), designed to impede specific proteins that facilitate the proliferation of cancerous cells.

More precisely, Sprycel targets the BCR-ABL protein, a product of the Philadelphia chromosome anomaly, which drives the uncontrolled multiplication of leukemia cells. By inhibiting the function of BCR-ABL, Sprycel works to decelerate or halt the advancement of CML and Ph+ ALL. Available in tablet form, Sprycel is typically administered orally once daily, with or without food. The appropriate dosage is determined by a healthcare professional, considering factors such as the type of leukemia, the patient's overall health, and any prior treatments. Similar to other medications, Sprycel may entail potential side effects. Common ones encompass fatigue, headache, diarrhea, nausea, and skin rash. Consistent monitoring and open communication with a healthcare provider are imperative for managing potential side effects. Patients should inform their clinician about any other medications, supplements, or existing medical conditions, as these may interact with Sprycel. Moreover, pregnant or breastfeeding individuals should thoroughly discuss the risks and benefits of taking Sprycel with their healthcare provider.

FutureWise Market Research has published a report that provides an insightful analysis of Sprycel Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Sprycel Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Bristol-Myers Squibb (BMS)
  • Novartis
  • Teva Pharmaceutical Industries
  • Mylan
  • Accord Healthcare
  • Sun Pharma
  • Reddy's Laboratories
  • Aurobindo Pharma

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Sprycel Market:

  • In 2021, Asciminib (marketed as Sprout) received approval as a pioneering allosteric inhibitor of BCR: ABL1 kinase activity. It is indicated for treating individuals with chronic-phase Chronic Myeloid Leukemia (CML) who have not responded to two prior lines of therapy or for those with the T315I mutation.

The Sprycel market is influenced by several key factors that aid in growth and demand. Firstly, the effectiveness of Sprycel in treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) plays a significant role. Its ability to target the BCR-ABL protein, a vital driver of these diseases, positions it as a valuable therapeutic option. Additionally, ongoing research and clinical trials exploring potential applications of Sprycel in other types of cancer, such as gastrointestinal stromal tumors (GIST), expand its market potential. Furthermore, the prevalence of CML and Ph+ ALL cases globally, along with increasing awareness and early diagnosis of these conditions, drives the demand for Sprycel.

While Sprycel offers substantial benefits in treating CML and Ph+ ALL, certain factors can restrain its market growth. Firstly, the high cost associated with Sprycel treatment can be a significant barrier, particularly in regions with limited access to healthcare resources or for patients without adequate insurance coverage. Additionally, potential side effects and adverse reactions associated with Sprycel may influence treatment decisions. Balancing its benefits with the risk of side effects is a crucial consideration for healthcare providers. Moreover, the emergence of alternative treatments and therapies for CML and Ph+ ALL, including other tyrosine kinase inhibitors and immunotherapies, introduces competitive dynamics that can impact the market share of Sprycel and restrain the market growth.

By Demographic

  • Age
  • Gender
  • Income

By Psychographic

  • Lifestyle
  • Attitudes

By Behavioral

  • Usage Rate
  • Compliance
  • Treatment History

By Medical

  • Indication
  • Disease Stage

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the increasing prevalence of CML and Ph+ ALL. According to the World Health Organization, CML is the most common type of leukemia, with an estimated 200,000 new cases diagnosed yearly. Ph+ ALL is a rare type of leukemia, but it is more aggressive than CML and is often fatal. Conversely, the European region is poised for substantial expansion in the forecast period due to the increasing prevalence of CML and an escalating demand for high-quality healthcare services.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Sprycel Market By Demographic, By Psychographic, By Behavioral, By Medical, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction

    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology

    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary

    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Sprycel Market Variables, Trends & Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview

    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Sprycel Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Sprycel Market Analysis Tools

    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Sprycel Market, By Demographic Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Age
      2. Gender
      3. Income
  • 8.  Sprycel Market, By Psychographic Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Lifestyle
      2. Attitudes
  • 9.  Sprycel Market, By Behavioral Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Usage Rate
      2. Compliance
      3. Treatment History
  • 10.  Sprycel Market, By Medical Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Indication
      2. Disease Stage
  • 11.  North America Sprycel Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 12.  Latin America Sprycel Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 13.  Europe Sprycel Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 14.  Asia Pacific Sprycel Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 15.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 16.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Bristol-Myers Squibb (BMS)
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Novartis
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Teva Pharmaceutical Industries
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Mylan
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Accord Healthcare
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Sun Pharma
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Reddy's Laboratories
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Aurobindo Pharma
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client

    •   


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11